*** Siga Technologies Assigned Patent ALEXANDRIA, Va., April 5 -- Siga Technologies, New York, has been assigned a patent (8,410,149) developed by five co-inventors for "sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses." The co-inventors are Dongcheng Dai, Corvallis, Ore., Tove Bolken, Keizer, Ore., Sean M. Amberg, Corvallis, Ore., Dennis E. Hruby, Albany, Ore., and Thomas R. Bailey, Phoenixville, Pa.
Researchers wearing protective clothing investigate the 1993 HPS outbreak.
Viral hemorrhagic fevers (VHFs) refer to a group of illnesses that are caused by several distinct families of viruses. In general, the term "viral hemorrhagic fever" is used to describe a severe multisystem syndrome (multisystem in that multiple organ systems in the body are affected). Characteristically, the overall vascular system is damaged, and the body's ability to regulate itself is impaired. These symptoms are often accompanied by hemorrhage (bleeding); however, the bleeding is itself rarely life-threatening. While some types of hemorrhagic fever viruses can cause relatively mild illnesses, many of these viruses cause severe, life-threatening disease.
The Special Pathogens Branch (SPB) primarily works with hemorrhagic fever viruses that are classified as biosafety level four (BSL-4) pathogens. A list of these viruses appears in the SPB disease information index. The Division of Vector-Borne Infectious Diseases, also in the National Center for Infectious Diseases, works with the non-BSL-4 viruses that cause two other hemorrhagic fevers, dengue hemorrhagic fever and yellow fe